Update on anti-angiogenic treatment for malignant gliomas

Current Oncology Reports

Volumn 16, Issue 4, 2014, Pages

  De Groot, John F ^a   Mandel, Jacob J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Anti angiogenic treatment; Brain tumor; Gliomas; Malignant gliomas; Neuro oncology; Oncology; Treatment

Indexed keywords

6 O METHYLGUANINE; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; BIOLOGICAL MARKER; IRINOTECAN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROCARBAZINE; SOMATOMEDIN BINDING PROTEIN 2; TEMOZOLOMIDE;

ANAPLASTIC GLIOMA; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; CANCER DIAGNOSIS; CANCER RECURRENCE; DRUG APPROVAL; DRUG EFFICACY; FOOD AND DRUG ADMINISTRATION; GENE SILENCING; GLIOBLASTOMA; HEALTH CARE QUALITY; HUMAN; MGMT NONMETHYLATED GLIOBLASTOMA; MONOTHERAPY; MULTICENTER STUDY (TOPIC); OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; TUMOR VASCULARIZATION; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL TRIAL (TOPIC); GLIOMA; NEOVASCULARIZATION (PATHOLOGY); VASCULARIZATION;

ANGIOGENESIS INHIBITORS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CLINICAL TRIALS AS TOPIC; GLIOMA; HUMANS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84893173949     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-014-0380-6     Document Type: Review

References (51)

1. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359(5):492-507.
2. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-96. (Pubitemid 40349501)
3. Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol. 2010;120(6):707-18. doi:10.1007/s00401-010-0781-z.
4. Tanaka S, Louis DN, Curry WT, Batchelor TT, Dietrich J. Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end? Nat Rev Clin Oncol. 2013;10:14 -26. doi:10.1038/nrclinonc.2012.20.
5. Norden AD, Drappatz J, Wen PY. Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol. 2008;7(12):1152-60.
6. Chi AS, Gregory Sorensen A, Jain RK, Batchelor TT. Angiogenesis as a therapeutic target in malignant gliomas. Oncologist. 2009;14(6):621-36.
7. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 1990;82(1):4-6. (Pubitemid 20020880)
8. Wong MLH, Prawira A, Kaye AH, Hovens CM. Tumour angiogenesis: its mechanism and therapeutic implications in malignant gliomas. J Clin Neurosci. 2009;16(9):1119-30.
9. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-42. (Pubitemid 38702844)
10. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542-50. (Pubitemid 44917502)
11. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666-76.
12. Brem S, Cotran R, Folkman J. Tumor angiogenesis: a quantitative method for histologic grading. Natl Cancer Inst. 1972;48:347-56.
13. Salmaggi A, Eoli M, Frigerio S, et al. Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma. J Neurooncol. 2003;62:297-303. (Pubitemid 36591966)
14. Cohen MH, Shen YL, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist. 2009;14:1131-8.
15. • Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733-40. doi:10.1200/JCO.2008.19.8721. Multi-center phase II study of bevacizumab or bevacizumab plus irinotecan in recurrent glioblastoma showing improvement in radiographic response and 6 month PFS compared to historical controls leading to FDA Approval.
16. • Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27:740-5. N.I.H. phase II study of bevacizumab alone showing improvement in radiographic response and 6 month PFS recurrent glioblastoma compared to historical controls leading to FDA Approval.
17. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999;17(8):2572-8. (Pubitemid 29368260)
18. Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000;83:588-93. (Pubitemid 30636298)
19. Macdonald DR, Cascino TL, Schold SCJ, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277-80. (Pubitemid 20195640)
20. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007;11:83-95. (Pubitemid 46075199)
21. Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 2008;70(10):779-87.
22. Chi AS, Norden AD, Wen PY. Antiangiogenic strategies for treatment of malignant gliomas. Neurotherapeutics. 2009;6(3):513-26.
23. • Gilbert MR, Dignam J, Won M, et al. RTOG 0825: phase III double-blind placebo-controlled trial evaluating bevacizumab in patients with newly diagnosed glioblastoma. Proc Am Soc Clin Oncol. 2013; Abstract 1. Phase 3 double-blind placebo-controlled trial evaluating the addition of bevacizumab to the current standard of care (Stupp regimen) in patients with newly diagnosed glioblastoma that did not show a significant improvement in PFS or OS.
24. • Wick W, Cloughesy TF, Nishikawa R, et al. Tumor response based on adapted Macdonald criteria and assessment of pseudoprogression in the phase III AVAglio trial of bevacizumab plus temozolomide plus radiotherapy in newly diagnosed glioblastoma patients. Proc Am Soc Clin Oncol. 2013; Abstract 2002. Phase 3 double-blind placebo-controlled trial evaluating the addition of bevacizumab to the current standard of care (Stupp regimen) in patients with newly diagnosed glioblastoma that showed a significant improvement in PFS of 3 months but no benefit in OS.
25. Wefel JS, Pugh SL, Armstrong TS, et al. Neurocognitive function outcomes in patients with glioblastoma enrolled in RTOG 0825. Proc Am Soc Clin Oncol. 2013; Abstract 2004.
26. Armstrong TS, Won M, Wefel JS, Gilbert MR et al. Comparative impact of treatment on patient reported outcomes (PROs) in patients with glioblastoma (GBM) enrolled in RTOG 0825. Proc Am Soc Clin Oncol. 2013; Abstract 2003.
27. Rahmathulla G, Hovey EJ, Hashemi-Sadraei N, Ahluwalia MS. Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges. Oncol Targets Ther. 2013;6:371-89. doi:10.2147/OTT.S38628. Published online 2013 April 15.
28. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008;8(8):592-603.
29. Ananthnarayan S, Bahng J, Roring J, et al. Time course of imaging changes of GBMduring extended bevacizumab treatment. J Neuro-Oncol. 2008;88(3):339-47.
30. Quant EC, Norden AD, Drappatz J, et al. Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro-Oncology. 2009;11(5):550-5.
31. de Groot JF, Fuller G, Kumar AJ, et al. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro-Oncology. 2010;12(3):233-42.
32. Piao Y, Liang J, Holmes L, Henry V, Sulman E, de Groot JF. Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition. Clin Cancer Res. 2013;19(16):4392-403. doi:10.1158/1078-0432.CCR- 12-1557.
33. Wick A, Dörner N, Schäfer N, Hofer S, Heiland S, Schemmer D, et al. Bevacizumab does not increase the risk of remote relapse in malignant glioma. Ann Neurol. 2011;69(3):586-92. doi:10.1002/ana.22336.
34. Hegi ME, Diserens A-C, Gorlia T, Hamou M-F, De Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997-1003. doi:10.1056/NEJMoa043331. (Pubitemid 40349502)
35. Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M, et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT. J Clin Oncol. 2008;26(25):4189-99. doi:10.1200/JCO.2007.11.5964.
36. Herrlinger U, Schaefer N, Steinbach JP, et al. Bevacizumab, irinotecan, and radiotherapy versus standard temozolomide and radiotherapy in newly diagnosed MGMT non-methylated glioblastoma patients: first results from the randomized multicenter GLARIUS trial. Proc Am Soc Clin Oncol. 2013; Abstract LBA2000.
37. • Taal W, Oosterkamp HM, Walenkamp AM, et al. A randomized phase II study of bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma: the Dutch BELOB study. Proc Am Soc Clin Oncol. 2013; Abstract 2001. Phase II study showing benefit in 6 month PFS and OS with combination of treatment with bevacizumab and lomustine compared to either agent alone. First bevacizumab study in recurrent glioblastoma to show benefit in overall survival as a primary endpoint.
38. Shirai K, Siedow MR, Chakravarti A. Antiangiogenic therapy for patients with recurrent and newly diagnosed malignant gliomas. J Oncol. 2012;2012:193436. doi:10.1155/2012/193436.
39. Stupp R, Hegi ME, Neyns B, Goldbrunner R, Schlegel U, Clement PM, et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010;28(16):2712-8. doi:10.1200/JCO.2009.26.6650.
40. Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma and methylated 06-methylguanine-DNA-methyltransferase (MGMT) gene promoter: key results of themulticenter, randomized open-label, controlled, phase III CENTRIC study. Proc Am Soc Clin Oncol. 2013; Abstract LBA2009.
41. Desjardins A, Reardon DA, Herndon JE 2nd, Marcello J, Quinn JA, Rich JN, et al. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clinical cancer research: an official journal of the American Association for Cancer Research. Clinical Trial, Phase II, Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't. 2008;14(21):7068-73.
42. Vredenburgh JJ, Desjardins A, Herndon 2nd JE, Dowell JM, Reardon DA, Quinn JA, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007;1513(4):1253-9. (Pubitemid 46424067)
43. Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol. 1999;17(9):2762-71. (Pubitemid 29415233)
44. Duda DG, Batchelor TT, Willett CG, Jain RK. VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Trends Mol Med. 2007;13:223-30. (Pubitemid 46836870)
45. Sathornsumetee S, Cao Y, Marcello JE, et al. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol. 2008;26(2):271-8.
46. Sathornsumetee S, Desjardins A, Vredenburgh JJ, et al. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro-Oncology. 2010;12(12):1300-10.
47. Sulman EP, Won M, Blumenthal DT, et al. Molecular predictors of outcome and response to bevacizumab based on analysis of RTOG 0825, a phase III trial comparing chemoradiation with and without bevacizumab in patients with newly diagnosed glioblastoma. Proc Am Soc Clin Oncol. 2013; Abstract LBA2010.
48. Vredenburgh J, Desjardins A, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25(30):4722-9. (Pubitemid 350086473)
49. Chen W, Delaloye S, Silverman DH, Geist C, Czernin J, Sayre J, et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol. 2007;25(30):4714-21. (Pubitemid 350086472)
50. Gutin PH, Iwamoto FM, Beal K, Mohile NA, Karimi S, Hou BL, et al. Safety efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys. 2009;75(1):156-63. doi:10.1016/j.ijrobp.2008.10.043.
51. Hasselbalch B, Lassen U, Hansen S, Holmberg M, Sørensen M, Kosteljanetz M, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. Neurol Oncol. 2010;12(5):508-16. doi:10.1093/neuonc/nop063.